| Assessment Status | Assessment process complete |
| HTA ID | 20052 |
| Drug | Galcanezumab |
| Brand | Emgality® |
| Indication | For the prophylaxis of migraine in adults who have at least four migraine days per month. |
| Assessment Process | |
| Rapid review commissioned | 02/12/2020 |
| Rapid review completed | 13/01/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of galcanezumab (Emgality®) on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations March 2022.